It is plausible that modulation, namely upregulation of CCL8 activity, in combination with other chemokine–cytotoxic drug combinations, may provide a novel strategy for the management of breast and other cancers, depending on their specific responsiveness to specific chemokines. Here, CCL8 is linked to cancer.